Physician profile
Sheng Li
NPI 1376770602
$43,837.77
in general payments reported to CMS, 2019-2025
9 companies · $5,648 in 2025
The $5,648 reported for 2025 was more than what 97% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,271 · 2021: $5,793 · 2022: $7,747 · 2023: $5,175 · 2024: $18K · 2025: $5,648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $20K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,780 · Travel and Lodging: $3,120 · Food and Beverage: $1,567 · Honoraria: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $19,810.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,780.00 |
| Travel and Lodging | $3,119.68 |
| Food and Beverage | $1,567.17 |
| Honoraria | $750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $17,106.88 | 2022-2025 | |
| Pacira Pharmaceuticals Incorporated | $11,209.68 | 2022-2025 | Iovera, Zilretta, Exparel |
| Merz Pharmaceuticals, LLC | $7,832.07 | 2021-2025 | Xeomin |
| Saol International Limited | $5,610.00 | 2021 | |
| Saol Therapeutics INC. | $1,650.00 | 2019-2022 | |
| Microtransponder, INC. | $162.24 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $128.46 | 2025 | Dysport |
| Merz North America, INC. | $116.30 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.14 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheng Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.